More importantly, MR imaging using CD81-MPIO as a contrast agent may provide a noninvasive tool to explore expression of CD81 and its corresponding gene functions linked to the genesis, development, prognosis of atherosclerosis, and susceptibility to antiatherosclerosis drugs. This evidence concerns the gene CD81 and atherosclerosis.